These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29337202)

  • 1. Progress with covalent small-molecule kinase inhibitors.
    Zhao Z; Bourne PE
    Drug Discov Today; 2018 Mar; 23(3):727-735. PubMed ID: 29337202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of targeted covalent inhibitors.
    Lonsdale R; Ward RA
    Chem Soc Rev; 2018 Jun; 47(11):3816-3830. PubMed ID: 29620097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.
    Lu X; Smaill JB; Patterson AV; Ding K
    J Med Chem; 2022 Jan; 65(1):58-83. PubMed ID: 34962782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective and potent small-molecule inhibitors of PI3Ks.
    Jeong Y; Kwon D; Hong S
    Future Med Chem; 2014 May; 6(7):737-56. PubMed ID: 24941870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and strategies of VEGFR-2/KDR inhibitors.
    Huang L; Huang Z; Bai Z; Xie R; Sun L; Lin K
    Future Med Chem; 2012 Sep; 4(14):1839-52. PubMed ID: 23043480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-based design of kinase inhibitors: a practical guide.
    Erickson JA
    Methods Mol Biol; 2015; 1289():157-83. PubMed ID: 25709040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ins and outs of selective kinase inhibitor development.
    Müller S; Chaikuad A; Gray NS; Knapp S
    Nat Chem Biol; 2015 Nov; 11(11):818-21. PubMed ID: 26485069
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
    Chaudhary D; Robinson S; Romero DL
    J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons learned from molecular scaffold analysis.
    Hu Y; Stumpfe D; Bajorath J
    J Chem Inf Model; 2011 Aug; 51(8):1742-53. PubMed ID: 21755989
    [No Abstract]   [Full Text] [Related]  

  • 11. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.
    Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I
    J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covalent docking of large libraries for the discovery of chemical probes.
    London N; Miller RM; Krishnan S; Uchida K; Irwin JJ; Eidam O; Gibold L; Cimermančič P; Bonnet R; Shoichet BK; Taunton J
    Nat Chem Biol; 2014 Dec; 10(12):1066-72. PubMed ID: 25344815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.
    Breen ME; Soellner MB
    ACS Chem Biol; 2015 Jan; 10(1):175-89. PubMed ID: 25494294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.
    Fischer PM
    Med Res Rev; 2017 Mar; 37(2):314-367. PubMed ID: 27775829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors.
    Li B; Rong D; Wang Y
    Curr Top Med Chem; 2019; 19(21):1872-1876. PubMed ID: 31696799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promiscuity and selectivity of small-molecule inhibitors across TAM receptor tyrosine kinases in pediatric leukemia.
    Liu MH; Chen SB; Yu J; Liu CJ; Zhang XJ
    J Mol Graph Model; 2017 Aug; 75():125-131. PubMed ID: 28551502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors.
    Akritopoulou-Zanze I; Hajduk PJ
    Drug Discov Today; 2009 Mar; 14(5-6):291-7. PubMed ID: 19121409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing the kinase field: new targets and second generation inhibitors.
    Laufer S; Bajorath J
    J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
    Zhao H; Huang D; Caflisch A
    ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unravelling the structural interactions between PKR kinase domain and its small molecule inhibitors using computational approaches.
    Barage S; Kulkarni A; Pal JK; Joshi M
    J Mol Graph Model; 2017 Aug; 75():322-329. PubMed ID: 28628858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.